Clinical Trial Update: Phase III Study ：SHR6390/Placebo Combined With Endocrine Therapy for the Adjuvant Treatment of Hormone Receptor Positive,Human Epidermal Receptor 2 Negative [Phase 3]

View source ↗

Summary

Phase III trial status update for SHR6390 in combination with placebo and endocrine therapy as adjuvant treatment for hormone receptor-positive, HER2-negative b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• SHR6390 (SHR6390)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING